Navigation Links
RxElite Files Registration Statement with Securities and Exchange Commission
Date:10/12/2007

MERIDIAN, Idaho, Oct. 12 /PRNewswire-FirstCall/ -- RxElite Holdings, Inc., a wholly owned operating subsidiary of Southridge Technology Group, Inc. (OTC Bulletin Board: SOUT) and a developer, manufacturer, and marketer of specialty generic prescription drug products, announced the filing of their Registration Statement with the Security and Exchange Commission for sale of shares from their recent round of financing.

"We are pleased to report that we are meeting our stipulated obligations with our investors promptly," commented Jonathan Houssian, the President and Founder of RxElite. "This is evidence of our growth as a public company and of the results oriented culture we have nurtured over the last 7 years."

RxElite filed the registration statement within the agreed to period detailed in their private placement concluded on July 13, 2007. The statement registers 53,747,555 shares of common stock, of which 35,831,706 were issued to investors in the private placement and the remainder that may be issued in the future through the exercise of warrants held by the same investors. Total shares of common stock outstanding for the company are 83,755,554. According to the private placement agreement, the recently registered shares must be declared effective within 90 days.

About RxElite Holdings, Inc.

RxElite Holdings, Inc. develops, manufactures, and markets generic prescription drug products in specialty generic markets. These markets include products in the areas of anesthesia, sterile liquid dose drugs (including respiratory inhalation drugs, ophthalmics, and injectable drugs), and transdermal patch products.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 involving known and unknown risks, delays, and uncertainties that may cause the our actual results or performance to differ materially from those expressed or implied by these forward-looking statements. These risks, delays, and uncertainties include, but are not limited to: risks associated with the uncertainty of future financial results, our reliance on our sole supplier, the limited diversification of our product offerings, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission. The Company's Form SB-2, filed with the SEC on October 10, 2007 details the registration of shares through the private placement. The Company undertakes no obligation to update any forward-looking statements.

Contact:

Corporate Information

Ph: (208) 288-5550

Toll Free: (800) 414-1901

Fax: (208) 288-1191

Investor Relations

Charlie Forshee, 215-885-4981

investorrelations@rxelite.com

Segue Ventures LLC


'/>"/>
SOURCE RxElite Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Novartis files application with FDA for Zometa
2. AAI Pharma Files Lawsuit Against Dr. Reddys Laboratories
3. Unfavourable Lipid-Lipoprotein profiles in older adults has been linked to abdominal visceral fat
4. Understanding Gene Profiles Could Help Cure A Resistant Form Of Leukemia In Kids
5. Personality profiles of gamblers and substance abusers are similar
6. NGO Files Pre-Grant Opposition Against Anti-HIV Drug, Combivir
7. Venus Remedies Files 5th International Patent Application
8. Shoaib Akhtar files appeal against ban
9. AIIMS Official Files Complaint Against Venugopal
10. Glaxo Files Cancer Drug For Approval With FDA
11. Nigeria Files New Lawsuit Against Pfizer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... Florida (PRWEB) , ... August 15, 2017 , ... ... cold therapy products, announced today the introduction of the innovative new 10x10 bladder ... for post-operative patients. The plush design enhances comfort and enables the patient to ...
(Date:8/15/2017)... ... August 15, 2017 , ... Dr. Timothy Davis is ... periodontal disease . This information can be used to develop patient-specific treatment plans ... two salivary diagnostic tests, named MyPerioPath® and MyPerioID® are offered by OralDNA® Labs, ...
(Date:8/15/2017)... ... August 15, 2017 , ... ... communication, promotion, crisis management using Artificial Intelligence. Published through FirstAlign’s Center of ... well as providing guidance in support of public crisis decisions. , People remember ...
(Date:8/15/2017)... Alpharetta, GA (PRWEB) , ... August 15, 2017 ... ... solutions for providers and health plans, announced today it has relocated its corporate ... , “We partner closely with our clients to navigate the complexities of healthcare ...
(Date:8/15/2017)... ... August 15, 2017 , ... Schools, ... eating Fajita Pete's fresh food when they sign up for a Spirit Night ... will receive 15 percent of sales from customers who mention the fundraiser from ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... Flight Network and PeaceHealth Oregon Network announced they renewed a ... efficiency for patients at hospitals in Eugene ... , and Florence, Oregon , who ... work collaboratively to move patients who require the highest level ... emergency exists. PeaceHealth ...
(Date:8/1/2017)...   CerSci Therapeutics , a non-opioid drug development ... has received notice from the National Institute on Drug ... that it has been awarded a Direct-to-Phase II Small ... 2017 with an additional $1,000,000 to follow in 2018. ... of their lead non-opioid drug candidate CT-044 to the ...
(Date:7/31/2017)... , July 31, 2017 Three Tru-D SmartUVC ... South Korea . Tru-D, short for "Total Room Ultraviolet ... operating rooms after an environmental services (ES) professional cleans the area with ... ... "Although the BAACH ...
Breaking Medicine Technology: